Commercial: FDA / EGFR / Opdivo plus Yervoy | Vanderbilt Television News Archive

Commercial: FDA / EGFR / Opdivo plus Yervoy #1316813

CBS Evening News for Monday, Apr 26, 2021
View other clips in this broadcast →

Material supplied by VTNA may be used for educational analysis or research only. Any editing, reproduction, publication, rebroadcast, public showing or public display may be prohibited by copyright laws.

Advanced non small cell lung cancer can change everything, but your first treatment could be a chemo free combination of two immunotherapies that works differently. It could mean a chance to live longer Opdivo plus Yervoy is for adults newly diagnosed with non small cell lung cancer that has spread test positive for PDL one and does not have an abnormal EGFR or ALK gene. Opdivo plus Yervoy is the only FDA approved combination of two immunotherapies. Opdivo plus Yervoy equals a chance for more s...

Duration:: 00:01:30

Note to sponsor members: The Vanderbilt Television News Archive video player requires a modern operating system and browser to work properly. If you are experiencing playback problems, check the minimum requirements and adjust your setup accordingly. After adjustments, if you continue to experience problems, please contact us.

Welcome! Above is the abstract of the item that you're interested in viewing from the Vanderbilt Television News Archive's collection. You have three options if you'd like to view this item:

You may request a loan of this video by registering on our website and placing an order.
You may visit the Television News Archive on the Vanderbilt campus to view on-site from the Archive's collection.
If you are associated with a college or university, you may ask your library if they would like to become a sponsor, which would give students and faculty at your institution the ability to view items from our collection.

If you believe that you are associated with a sponsoring college or university and have received this message in error, please let us know.